Month: August 2023

NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimen NKX019 clinical data presented at EHA 2023 and ICML 2023 meetings Clinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024 Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2023. “Nkarta remains well positioned to advance allogeneic cell therapy and lead the development of groundbreaking natural killer cell therapy...

Revenue was $471.9 million, a 6.5% increase over the prior yearGross margin increased 7.0% to $155.3 million, compared to Q2 2022Net income was $25.6 million, compared to net loss of $473.9 million in the comparable prior year periodAdjusted EBITDA was $35.8 million, a sequential increase of 25.6% and a 3.2% decrease as compared to the prior yearFull year 2023 revenue guidance raised to a range of $1,850 million to $1,860 millionFull year 2023 Adjusted EBITDA guidance raised to a range of $132 million to $135 millionATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and six-month periods ended July 1, 2023. Jeff...

Company receives further regulatory clarity from FDA on Phase 3 ENABLAR-2 study. Potential for enobosarm +/- abemaciclib accelerated approval pathway in metastatic breast cancer, if successful based on new FDA Guidance Company plans to expand sabizabulin Phase 3 confirmatory study to include all types of viral induced lung infections (influenza, RSV and COVID-19) in hospitalized patients requiring supplemental oxygen who are at risk for ARDS Company reported positive separate preclinical data for sabizabulin against both influenza and against poxvirus; FDA preIND meeting for sabizabulin against poxvirus set for August 2023 Company-owned telehealth digital platform making good progress; FC2 prescriptions growing ENTADFI® product sold for $20 million, plus up to an additional potential $80 million from sales milestones Company’s cash burn...

WILLIAMSBURG, Va., Aug. 10, 2023 (GLOBE NEWSWIRE) — Sotherly Hotels Inc. (NASDAQ: SOHO), (“Sotherly” or the “Company”), a self-managed and self-administered lodging real estate investment trust (a “REIT”), today reported its consolidated results for the second quarter ended June 30, 2023. The Company’s results include the following*:  Three Months Ended   Six Months Ended    June 30, 2023   June 30, 2022   June 30, 2023   June 30, 2022    ($ in thousands except per share data)   ($ in thousands except per share data)  Total revenue $ 49,017   $ 47,170   $ 92,509   $ 85,523  Net income attributable to common stockholders   3,133     24,269     2,551     21,762                   EBITDA   14,103     37,552     24,051     47,005  Hotel EBITDA   14,842     14,772     26,921     24,746                   FFO...

AFM13 combination with AB-101 NK cells (LuminICE-203): On track to report initial efficacy and safety data in the first half 2024; Type C meeting request submitted to FDA to clarify requirements for accelerated approval. AFM24 monotherapy: Clinical activity in 7 out of 15 heavily pretreated patients with EGFRmut non-small cell lung cancer (NSCLC), including 2 confirmed partial responses. AFM24 combinations: Affimed plans to report data from the combination with atezolizumab in the fourth quarter 2023; data from combination study with SNK01 were presented at ASCO Breakthrough. AFM28: Cleared second dose cohort without dose limiting toxicities in phase 1 dose escalation study in patients with CD123-positive relapsed/refractory (r/r) acute myeloid leukemia (AML); enrolling patients in third cohort. Cash runway into 2025: As of June 30, 2023,...

heart-1 Initial Clinical Data Expected in the Fourth Quarter of 2023 Preclinical Studies and Clinical Operations Activities Underway to Support Initiation of Clinical Trials for VERVE-102 and VERVE-201 in 2024 Lp(a) Program Advancing in Collaboration with Lilly; Received $60 Million in Combined Upfront Payment and Equity Investment in August 2023 Well-capitalized with Cash Runway into 2026 BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the second quarter of 2023. “We are dedicated to bringing life-changing, once-and-done medicines to patients with cardiovascular disease,” said Sekar Kathiresan, M.D.,...

Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with Schizophrenia DMX-1002 (Ibogaine) Phase 1 results enable discussions with regulatory authorities to assess progressing into proof-of-concept study in patients with Opioid Use Disorder The Company’s $227M cash position and committed term loan funding is expected to fund operations into 1H 2026NEW YORK and BERLIN, Aug. 10, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2023 financial results and provided corporate updates. “We continue to focus on our vision to heal mental health disorders so that everyone, everywhere can live...

BROOKFIELD, NEWS, Aug. 10, 2023 (GLOBE NEWSWIRE) — Brookfield Reinsurance (NYSE, TSX: BNRE) today announced financial results for the quarter ended June 30, 2023. Sachin Shah, CEO of Brookfield Reinsurance, stated, “The strength of our second quarter results are underpinned by significant investment portfolio redeployment and the execution of strategic initiatives post the acquisition of American National one year ago. Following the close of our announced transactions, our total insurance assets will be over $100 billion, representing an important milestone in the continued growth of a diversified insurance business of scale.”UnauditedAs at and for the periods ended June 30(US$ millions, except per share amounts) Three Months Ended   Six Months Ended  2023     2022     2023     2022Total assets1 $ 47,994   $ 40,700   $ 47,994   $ 40,700Adjusted...

Invested $50 billion and Monetized $15 billion of Assets YTD On Track to Achieve Record Inflows of Close to $150 billion in 2023 BROOKFIELD, NEWS, Aug. 10, 2023 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) today announced financial results for the quarter ended June 30, 2023. Nick Goodman, President of Brookfield Corporation, stated, “Financial performance was very strong during the second quarter, as our operations continued to generate stable and growing cash flows. Momentum continues to grow across the business; so far this year we have announced more than $50 billion of acquisitions, sold approximately $15 billion of assets, and are on track to achieve a record of close to $150 billion of inflows in 2023.” He added, “We continue to differentiate our franchise with nearly $120 billion of liquidity, strong access...